PMC3738556_01
Change in HbA1c levels in (A) patient 1, (B) patient 2, and (C) patient 3. In patient 1, a 53-year-old woman with type 2 diabetes mellitus, HbA1c levels decreased from 11.1% to 6.1% after addition of sitagliptin to ongoing metformin, glibenclamide, and miglitol therapy, although the dose of glibenclamide was decreased. In patient 2, a 74-year-old woman with type 2 diabetes mellitus being treated with metformin and glibenclamide, HbA1c levels decreased from 8.2% to 6.0% after the addition of sitagliptin to ongoing therapy and increasing metformin up to the maximum dose. In this patient, glibenclamide was ceased because of hypoglycemia and, instead, low-dose glimepiride was added. Patient 3, a 71-year-old woman with type 2 diabetes mellitus treated with metformin and sitagliptin, exhibited a decrease in HbA1c levels from 8.6% to 7.1% after the addition of glimepiride to ongoing therapy.. Abbreviation: CPR, C-peptide immunoreactivity.
jcm-3-2012-001f1.jpg
PMC3738556_03_jcm-3-2012-001f1.jpg
f1-jcm-3-2012-001
HbA1c levels improved, decreasing to 7.1% at 24 weeks after starting triple combination therapy (Fig. 1C). Her fasting plasma glucose also improved from 186 to 112 mg/dL following the decrease in HbA1c levels, and her body mass index was almost the same as prior to the addition of glimepiride (from 19.5 to 19.8 kg/m2, Table 1).
PMC3738556_02
Change in HbA1c levels in (A) patient 1, (B) patient 2, and (C) patient 3. In patient 1, a 53-year-old woman with type 2 diabetes mellitus, HbA1c levels decreased from 11.1% to 6.1% after addition of sitagliptin to ongoing metformin, glibenclamide, and miglitol therapy, although the dose of glibenclamide was decreased. In patient 2, a 74-year-old woman with type 2 diabetes mellitus being treated with metformin and glibenclamide, HbA1c levels decreased from 8.2% to 6.0% after the addition of sitagliptin to ongoing therapy and increasing metformin up to the maximum dose. In this patient, glibenclamide was ceased because of hypoglycemia and, instead, low-dose glimepiride was added. Patient 3, a 71-year-old woman with type 2 diabetes mellitus treated with metformin and sitagliptin, exhibited a decrease in HbA1c levels from 8.6% to 7.1% after the addition of glimepiride to ongoing therapy.. Abbreviation: CPR, C-peptide immunoreactivity.
jcm-3-2012-001f1.jpg
PMC3738556_03_jcm-3-2012-001f1.jpg
f1-jcm-3-2012-001
HbA1c levels improved, decreasing to 7.1% at 24 weeks after starting triple combination therapy (Fig. 1C). Her fasting plasma glucose also improved from 186 to 112 mg/dL following the decrease in HbA1c levels, and her body mass index was almost the same as prior to the addition of glimepiride (from 19.5 to 19.8 kg/m2, Table 1).
PMC3738556_03
Change in HbA1c levels in (A) patient 1, (B) patient 2, and (C) patient 3. In patient 1, a 53-year-old woman with type 2 diabetes mellitus, HbA1c levels decreased from 11.1% to 6.1% after addition of sitagliptin to ongoing metformin, glibenclamide, and miglitol therapy, although the dose of glibenclamide was decreased. In patient 2, a 74-year-old woman with type 2 diabetes mellitus being treated with metformin and glibenclamide, HbA1c levels decreased from 8.2% to 6.0% after the addition of sitagliptin to ongoing therapy and increasing metformin up to the maximum dose. In this patient, glibenclamide was ceased because of hypoglycemia and, instead, low-dose glimepiride was added. Patient 3, a 71-year-old woman with type 2 diabetes mellitus treated with metformin and sitagliptin, exhibited a decrease in HbA1c levels from 8.6% to 7.1% after the addition of glimepiride to ongoing therapy.. Abbreviation: CPR, C-peptide immunoreactivity.
jcm-3-2012-001f1.jpg
PMC3738556_03_jcm-3-2012-001f1.jpg
f1-jcm-3-2012-001
HbA1c levels improved, decreasing to 7.1% at 24 weeks after starting triple combination therapy (Fig. 1C). Her fasting plasma glucose also improved from 186 to 112 mg/dL following the decrease in HbA1c levels, and her body mass index was almost the same as prior to the addition of glimepiride (from 19.5 to 19.8 kg/m2, Table 1).